Grupo para la caracterización molecular de las neoplasias hematológicas
Hospital Universitario Príncipe de Asturias
Alcalá de Henares, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Príncipe de Asturias (27)
2024
-
COVID-19 Outcomes in Patients with Hematologic Malignancies in the Era of COVID-19 Vaccination and the Omicron Variant
Cancers, Vol. 16, Núm. 2
-
Correction to: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA (Scientific Reports, (2022), 12, 1, (13057), 10.1038/s41598-022-17271-3)
Scientific Reports
2023
2022
-
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA
Scientific Reports, Vol. 12, Núm. 1
2021
-
Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group
Leukemia and Lymphoma, Vol. 62, Núm. 12, pp. 2928-2938
-
Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study
Cancer Medicine, Vol. 10, Núm. 21, pp. 7629-7640
2020
-
Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis
Medicina Clinica, Vol. 155, Núm. 4, pp. 152-158
-
Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: Lessons from a large population-based registry study
Journal of Hematology and Oncology, Vol. 13, Núm. 1
-
Impacto de la Covid-19 en pacientes adultos con neoplasias hematológicas: informe del registro Covid-19 de la asociación madrileña de hematología y hemoterapia (AMHH)
Anales de la Real Academia Nacional de Medicina, Núm. 137, pp. 202-208
-
Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity
British Journal of Haematology, Vol. 189, Núm. 4, pp. 672-683
-
Jumping Translocation in a Patient with Acute Leukemia and Fatal Evolution
Case Reports in Oncology, Vol. 13, Núm. 2, pp. 1026-1030
-
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality
Blood Cancer Journal, Vol. 10, Núm. 10
2019
-
A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia
Haematologica, Vol. 104, Núm. 2, pp. 288-296
2017
-
Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea
Haematologica, Vol. 102, Núm. 1, pp. 103-109
2016
-
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation
Haematologica, Vol. 101, Núm. 8, pp. 926-931
-
Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method
Annals of Hematology, Vol. 95, Núm. 5, pp. 719-732
-
Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera
British Journal of Haematology, Vol. 172, Núm. 5, pp. 786-793
2015
-
Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia
Annals of Hematology, Vol. 94, Núm. 6, pp. 911-918
-
Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months
Cancer Medicine, Vol. 4, Núm. 7, pp. 995-1002
2014
-
Do chronic myeloid leukemia patients with late “warning” responses benefit from “watch and wait” or switching therapy to a second generation tyrosine kinase inhibitor?
American Journal of Hematology, Vol. 89, Núm. 11, pp. E206-E211